31450 Federal Register / Vol. 75, No. 106 / Thursday, June 3, 2010 / Notices 

and discussed at this meeting. These 

discussions are likely to reveal personal 

information concerning individuals 

associated with the applications. This 

information is exempt from mandatory 

disclosure under the above-cited 

statutes. 

SEP Meeting on: AHRQ Limited 

Competition: PROSPECT STUDIES— 

Building New Clinical Infrastructure for 

CE (R01). 

Date: June 16, 2010 (Open on June 16 

from 8 a.m. to 8:15 a.m. and closed for 

the remainder of the meeting). 

Place: Hyatt Regency Bethesda Hotel, 

7400 Wisconsin Avenue, 1 Bethesda 

Metro Center, Bethesda, Maryland 

20814. 

Contact Person: Anyone wishing to 

obtain a roster of members, agenda or 

minutes of the non-confidential portions 

of this meeting should contact Mrs. 

Bonnie Campbell, Committee 

Management Officer, Office of 

Extramural Research, Education and 

Priority Populations, AHRQ, 540 

Gaither Road, Room 2038, Rockville, 

Maryland 20850, Telephone (301) 427– 

1554. 

Agenda items for this meeting are 

subject to change as priorities dictate. 

Dated: May 24, 2010. 

Carol M. Clancy, 

Director. 

[FR Doc. 2010–13109 Filed 6–2–10; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality; Notice of Meeting 

In accordance with section 10(d) of 

the Federal Advisory Committee Act (5 

U.S.C., Appendix 2), announcement is 

made of a Health Care Policy and 

Research Special Emphasis Panel (SEP) 

meeting. 

A Special Emphasis Panel is a group 

of experts in fields related to health care 

research who are invited by the Agency 

for Healthcare Research and Quality 

(AHRQ), and agree to be available, to 

conduct on an as-needed basis, 

scientific reviews of applications for 

AHRQ support. Individual members of 

the Panel do not attend regularlyscheduled meetings and do not serve for 

fixed terms or a long period of time. 

Rather, they are asked to participate in 

particular review meetings which 

require their type of expertise. 

Substantial segments of the upcoming 

SEP meeting listed below will be closed 

to the public in accordance with the 

Federal Advisory Committee Act, 

section 10(d) of 5 U.S.C., Appendix 2 

and 5 U.S.C. 552b(c)(6). Grant 

applications for the OS ARRA: 

Optimizing Prevention and Healthcare 

Management for Complex Patients (R21) 

applications are to be reviewed and 

discussed at this meeting. These 

discussions are likely to reveal personal 

information concerning individuals 

associated with the applications. This 

information is exempt from mandatory 

disclosure under the above-cited 

statutes. 

SEP Meeting on: OS ARRA: 

Optimizing Prevention and Healthcare 

Management for Complex Patients 

(R21). 

Date: June 24, 2010 (Open on June 24 

from 8 a.m. to 8:15 a.m. and closed for 

the remainder of the meeting). 

Place: Hilton Rockville Executive 

Meeting Center, 1750 Rockville Pike, 

Conference Room TBD, Rockville, MD 

20850. 

Contact Person: Anyone wishing to 

obtain a roster of members, agenda or 

minutes of the nonconfidential portions 

of this meeting should contact Mrs. 

Bonnie Campbell, Committee 

Management Officer, Office of 

Extramural Research, Education and 

Priority Populations, AHRQ, 540 

Gaither Road, Room 2038, Rockville, 

Maryland 20850, Telephone (301) 427– 

1554. 

Agenda items for this meeting are 

subject to change as priorities dictate. 

Dated: May 24, 2010. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 2010–13108 Filed 6–2–10; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0004] 

[FDA 225–09–0014] 

Memorandum of Understanding by and 

Between the United States Food and 

Drug Administration and the 

International Anesthesia Research 

Society for the Safety of Key Inhaled 

and Intravenous Drugs in Pediatrics 

Public-Private Partnership 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is providing 

notice of a memorandum of 

understanding (MOU) between FDA and 

the International Anesthesia Research 

Society (IARS). The purpose of this 

MOU is to establish a framework for 

collaboration between FDA and IARS 

and to support their shared interest of 

promoting the safe use of anesthetics 

and sedatives in children. 

DATES: The agreement became effective 

March 21, 2010. 

FOR FURTHER INFORMATION CONTACT: 

Wendy R. Sanhai, Senior Scientific 

Advisor, Office of the Commissioner, 

Food and Drug Administration, 10903 

New Hampshire Ave., Bldg. 32, rm. 

4128, Silver Spring, MD 20993, 301– 

796–8518. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 20.108(c), 

which states that all written agreements 

and MOUs between FDA and others 

shall be published in the Federal 

Register, the agency is publishing notice 

of this MOU. 

Dated: May 26, 2010. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

BILLING CODE 4160–01–S 


sroberts on DSKD5P82C1PROD with NOTICES